210 related articles for article (PubMed ID: 24073410)
1. Intracellular secretory leukoprotease inhibitor modulates inositol 1,4,5-triphosphate generation and exerts an anti-inflammatory effect on neutrophils of individuals with cystic fibrosis and chronic obstructive pulmonary disease.
Reeves EP; Banville N; Ryan DM; O'Reilly N; Bergin DA; Pohl K; Molloy K; McElvaney OJ; Alsaleh K; Aljorfi A; Kandalaft O; O'Flynn E; Geraghty P; O'Neill SJ; McElvaney NG
Biomed Res Int; 2013; 2013():560141. PubMed ID: 24073410
[TBL] [Abstract][Full Text] [Related]
2. Inositol 1,4,5-triphosphate-mediated shuttling between intracellular stores and the cytosol contributes to the sustained elevation in cytosolic calcium in FMLP-activated human neutrophils.
Anderson R; Steel HC; Tintinger GR
Biochem Pharmacol; 2005 Jun; 69(11):1567-75. PubMed ID: 15896336
[TBL] [Abstract][Full Text] [Related]
3. Decreased levels of secretory leucoprotease inhibitor in the Pseudomonas-infected cystic fibrosis lung are due to neutrophil elastase degradation.
Weldon S; McNally P; McElvaney NG; Elborn JS; McAuley DF; Wartelle J; Belaaouaj A; Levine RL; Taggart CC
J Immunol; 2009 Dec; 183(12):8148-56. PubMed ID: 20007580
[TBL] [Abstract][Full Text] [Related]
4. Heat-aggregated IgA prepared from patients with IgA nephropathy increases priming of human neutrophils to produce inositol triphosphate following FMet-Leu-Phe stimulation in vitro.
Lai KN; Leung JC; Li PK
Nephron; 1995; 69(1):1-8. PubMed ID: 7891778
[TBL] [Abstract][Full Text] [Related]
5. Adenoviral E1A suppresses secretory leukoprotease inhibitor and elafin secretion in human alveolar epithelial cells and bronchial epithelial cells.
Higashimoto Y; Yamagata Y; Iwata T; Ishiguchi T; Okada M; Masuda M; Satoh H; Itoh H
Respiration; 2005; 72(6):629-35. PubMed ID: 16355004
[TBL] [Abstract][Full Text] [Related]
6. The role of cytosolic free calcium in the generation of inositol 1,4,5-trisphosphate and inositol 1,3,4-trisphosphate in HL-60 cells. Differential effects of chemotactic peptide receptor stimulation at distinct Ca2+ levels.
Lew PD; Monod A; Krause KH; Waldvogel FA; Biden TJ; Schlegel W
J Biol Chem; 1986 Oct; 261(28):13121-7. PubMed ID: 3489712
[TBL] [Abstract][Full Text] [Related]
7. Protease-antiprotease imbalances differ between Cystic Fibrosis patients' upper and lower airway secretions.
Hentschel J; Fischer N; Janhsen WK; Markert UR; Lehmann T; Sonnemann J; Böer K; Pfister W; Hipler UC; Mainz JG
J Cyst Fibros; 2015 May; 14(3):324-33. PubMed ID: 25286826
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia down-regulates expression of secretory leukocyte protease inhibitor in bronchial epithelial cells via TGF-β1.
Påhlman LI; Jögi A; Gram M; Mori M; Egesten A
BMC Pulm Med; 2015 Mar; 15():19. PubMed ID: 25851169
[TBL] [Abstract][Full Text] [Related]
9. Effects of native and oxidation-resistant secretory leukoprotease inhibitor on cystic fibrosis sputum: inhibition of neutrophil elastase activity and of sputum-induced secretion from porcine tracheal submucosal glands.
Schuster A; Hansen G; Zubrod-Eichert C; Wahn V
Pediatr Res; 1996 Nov; 40(5):732-7. PubMed ID: 8910939
[TBL] [Abstract][Full Text] [Related]
10. Protease-antiprotease imbalance in the lungs of children with cystic fibrosis.
Birrer P; McElvaney NG; Rüdeberg A; Sommer CW; Liechti-Gallati S; Kraemer R; Hubbard R; Crystal RG
Am J Respir Crit Care Med; 1994 Jul; 150(1):207-13. PubMed ID: 7912987
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of secretory leukocyte proteinase inhibitor in chronic obstructive lung disease: the role of TGF-beta/Smads signaling pathways.
Luo BL; Niu RC; Feng JT; Hu CP; Xie XY; Ma LJ
Arch Med Res; 2008 May; 39(4):388-96. PubMed ID: 18375249
[TBL] [Abstract][Full Text] [Related]
12. Anti-neutrophil elastase defense of the normal human respiratory epithelial surface provided by the secretory leukoprotease inhibitor.
Vogelmeier C; Hubbard RC; Fells GA; Schnebli HP; Thompson RC; Fritz H; Crystal RG
J Clin Invest; 1991 Feb; 87(2):482-8. PubMed ID: 1671391
[TBL] [Abstract][Full Text] [Related]
13. A quantitative investigation into the dependence of Ca2+ mobilisation on changes in inositol 1,4,5-trisphosphate levels in the stimulated neutrophil.
Thompson NT; Bonser RW; Tateson JE; Spacey GD; Randall RW; Hodson HF; Garland LG
Br J Pharmacol; 1991 Jun; 103(2):1592-6. PubMed ID: 1884113
[TBL] [Abstract][Full Text] [Related]
14. A secretory leukocyte protease inhibitor variant with improved activity against lung infection.
Camper N; Glasgow AM; Osbourn M; Quinn DJ; Small DM; McLean DT; Lundy FT; Elborn JS; McNally P; Ingram RJ; Weldon S; Taggart CC
Mucosal Immunol; 2016 May; 9(3):669-76. PubMed ID: 26376365
[TBL] [Abstract][Full Text] [Related]
15. Proteases and antiproteases in cystic fibrosis: pathogenetic considerations and therapeutic strategies.
Birrer P
Respiration; 1995; 62 Suppl 1():25-8. PubMed ID: 7792437
[TBL] [Abstract][Full Text] [Related]
16. Secretory leukocyte protease inhibitor inhibits neutrophil apoptosis.
Subramaniyam D; Hollander C; Westin U; Erjefält J; Stevens T; Janciauskiene S
Respirology; 2011 Feb; 16(2):300-7. PubMed ID: 21077989
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of recombinant secretory leukoprotease inhibitor aerosolized to normals and individuals with cystic fibrosis.
McElvaney NG; Doujaiji B; Moan MJ; Burnham MR; Wu MC; Crystal RG
Am Rev Respir Dis; 1993 Oct; 148(4 Pt 1):1056-60. PubMed ID: 8105734
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the inflammatory action of interleukin-1 and tumor necrosis factor (alpha) on neutrophil function by pentoxifylline.
Sullivan GW; Carper HT; Novick WJ; Mandell GL
Infect Immun; 1988 Jul; 56(7):1722-9. PubMed ID: 2838424
[TBL] [Abstract][Full Text] [Related]
19. Effects of scalaradial, a novel inhibitor of 14 kDa phospholipase A2, on human neutrophil function.
Barnette MS; Rush J; Marshall LA; Foley JJ; Schmidt DB; Sarau HM
Biochem Pharmacol; 1994 Apr; 47(9):1661-7. PubMed ID: 8185681
[TBL] [Abstract][Full Text] [Related]
20. Neutrophil activation in severe, early-onset COPD patients versus healthy non-smoker subjects in vitro: effects of antioxidant therapy.
Milara J; Juan G; Peiró T; Serrano A; Cortijo J
Respiration; 2012; 83(2):147-58. PubMed ID: 22094549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
